Anti-idiotype colorectal cancer vaccine - GlaxoSmithLine

Drug Profile

Anti-idiotype colorectal cancer vaccine - GlaxoSmithLine

Alternative Names: anti-idiotype goat antibody vaccine SCV 106; SCV 106; SDZ SCV 106

Latest Information Update: 16 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 02 Mar 2015 GlaxoSmithKline acquires Anti-idiotype colorectal cancer vaccine from Novartis
  • 02 Feb 2000 Investigation in Cancer in Austria (SC)
  • 02 Feb 2000 Investigation in Cancer in Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top